A practical reference on circadian rhythm: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-04-21 and is reviewed periodically as new material appears.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule nuclear receptor ligand |
| Appearance | Off-white to pale yellow solid | Typical for research-grade powder |
| Solubility class | Soluble in DMSO; low water solubility | Common stock solutions use organic solvent |
| Typical stock solvent | Dimethyl sulfoxide | Used for laboratory assays |
| Common analytical method | HPLC with UV or mass detection | Used for identity and purity checks |
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
"In a country devoid of national consciousness since its very foundation in 1830, and torn by intense regionalism and the rivalry between the cities of Quito –capital city–, and Guayaquil –economic nucleus of the nation–, anti-Peruvianism became the only pole of attraction capable of uniting all Ecuadorians, although in Peru a general feeling of anti-Ecuadorianism perhaps never took root –with the exception of Iquitos and the northeastern regions bordering Ecuador, paradoxically the same territories over which the Ecuador insisted on claiming as its own"
The Asmara College of Health Sciences is a public college in Asmara, Eritrea. It was founded in 1999 (1999) as one of the faculties at the University of Asmara with the aim of creating competent health professionals to meet the health needs of the nation. The college acquired its present independent status in 2005. The college has five major branches, namely: the School of Allied Health Professions, the School of Nursing, the School of Pharmacy, the School of Public Health, and the Department of Basic and Behavioral Sciences. The college offers BSc degrees in nursing, public health, pharmacy, ophthalmology, midwifery, and clinical laboratory sciences. It also trains technicians to diploma level in pharmacy, dentistry, physiotheraphy, radiology, and laboratory research. Since the college was founded, 3145 students have graduated, of whom 45% are female.
LeuT, which is also a member of the NSS family that functions as an amino acid transporter, was crystallized from Aquifex aeolicus by Yamashita et al., and shares 20-25% identity in primary structure with the human neurotransmitter transporters. Therefore, the crystal structure of LeuT and its transport mechanism have been proven to be a good model system for the study of NSS proteins. Although detailed transport mechanism of the NSS proteins is not fully understood, it is clear that in order for transport to occur a rearrangement of large proteins needs to take place. LeuT has been co-crystallised with sertraline and (R)- and (S)-fluoxetine where the SSRIs have been found to bind as non-competitive inhibitors in a vestibule binding site (can be looked at as a second binding site), which is separated from the drugs binding site by the site chains of the two aromatic amino acids of the extracellular gate of the transport protein. The halogens on the SSRIs chemical structure all bind to the same HBP within LeuT and interact with similar amino acids, but the amino acid sequence in the HBP is highly preserved between LeuT and SERT. That suggest that in the human SERT the SSRIs also bind both at the same position and with similar manner, which is a key feature making the SSRIs selective for SERT. Conversely, there could be differences in their binding where the other part of the drug molecule will likely bind to SERT in a different way, given the diversity in their structure.
The therapeutic window is the amount of a medication between the amount that gives an effect (effective dose) and the amount that gives more adverse effects than desired effects. For instance, medication with a small pharmaceutical window must be administered with care and control, e.g. by frequently measuring blood concentration of the drug, since it easily loses effects or gives adverse effects.
Sources: en.wikipedia.org
According to Jay Garfield, in the first chapter, Nāgārjuna argues against a reified view of causality which sees dependent origination in terms of substantial powers (kriyā) of causation (hetu) that phenomena have as part of their intrinsic nature (svabhāva). Instead, Nāgārjuna sees dependent origination as a series of conditional relationships (pratyaya) that are merely nominal designations and "explanatorily useful regularities". According to Nāgārjuna, if something could exist inherently or essentially from its own side (and thus have its own inherent causal powers), change and dependent arising would be impossible. Nāgārjuna states that "if things did not exist without essence, the phrase, "when this exists so this will be," would not be acceptable." Jan Westerhoff notes that Nāgārjuna argues that cause and effect are "neither identical nor different nor related as part and whole, they are neither successive, nor simultaneous, nor overlapping." Westerhoff states that Nāgārjuna thinks all conceptual frameworks of causality that make use of such ideas are based on a mistaken presupposition which is that "cause and effect exist with their own svabhāva". Westerhoff further argues that for Nāgārjuna, causes and effects are both dependent on one another (conceptually and existentially) and neither one can exist independently. As such, he rejects four ways that something could be causally produced: by itself, by something else, by both, by nothing at all.
=== Other uses === Clonidine also has several off-label uses, and has been prescribed to treat psychiatric disorders including stress, hyperarousal caused by post-traumatic stress disorder, borderline personality disorder, and other anxiety disorders. It has also been studied as a way to calm acute manic episodes. Clonidine can be used in restless legs syndrome. It can also be used to treat facial flushing and redness associated with rosacea. It has also been successfully used topically in a clinical trial as a treatment for diabetic neuropathy. Clonidine can also be used for migraine headaches and hot flashes associated with menopause. Clonidine has also been used to treat refractory diarrhea associated with irritable bowel syndrome, fecal incontinence, diabetes, diarrhea associated with opioid withdrawal, intestinal failure, neuroendocrine tumors, and cholera. Clonidine can be used in the treatment of Tourette syndrome (specifically for tics). Clonidine has also had some success in clinical trials for helping to remove or ameliorate the symptoms of hallucinogen persisting perception disorder (HPPD). Photoswitchable derivatives of clonidine have been developed that behave as α receptor agonists (adrenoswitches). They can be applied topically in the cornea and allow controlling with light the pupillary reflex of blinded mice and locomotion in zebrafish larvae.
== Plays == Vera; or, The Nihilists (1880/1882) (text) The Duchess of Padua (1883) (text) Lady Windermere's Fan (1892) (text) A Woman of No Importance (1893) (text) An Ideal Husband (1895) (text) The Importance of Being Earnest (1895) (text) Salomé (1896) Translated from French by Lord Alfred Douglas (text) La Sainte Courtisane (Incomplete) (text) A Florentine Tragedy (Incomplete) (text) (Dates are dates of first performance, which approximate better to the probable date of composition than dates of publication.)
Mrs. Glover, the well-known Scientist, will receive applications for one week from ladies and gentlemen who wish to learn how to heal the sick without medicine, and with a success unequaled by any known method of the present day, at Dr. Kennedy's office, No. 71 South Common Street, Lynn, Mass. Lynn was a center of the shoe industry and most of Eddy's students were factory workers or artisans. She charged $100, raised a few weeks later to $300, for a three-week course of 12 lessons (reduced in 1888 to seven). Eddy based the lessons on a revised version of Quimby's "Questions and Answers" manuscript—now called "The Science of Man, by which the sick are healed, Embracing Questions and Answers in Moral Science"—and on three shorter manuscripts, "The Soul's Inquiry of Man", "Spiritualism", and "Individuality", which she had written for her classes. "Questions and Answers" began: "What is God?" The answer: "Principle, wisdom, love, and truth." Two books on mental healing appeared around that time that may have influenced Eddy's thinking: The Mental Cure (1869) and Mental Medicine (1872), both by Warren Felt Evans, another former patient of Quimby's. Eddy allowed her students to make copies of the manuscripts, but they were forbidden, under a $3,000 bond, from showing them to anyone. The students agreed to pay Eddy 10 percent annually of income derived from her work, and $1,000 if they failed to practice or teach it.
A motor nerve, or efferent nerve, is a nerve that contains exclusively efferent nerve fibers and transmits motor signals from the central nervous system (CNS) to the effector organs (muscles and glands), as opposed to sensory nerves, which transfer signals from sensory receptors in the periphery to the CNS. This is different from the motor neuron, which includes a cell body and branching of dendrites, while the nerve is made up of a bundle of axons. In the strict sense, a "motor nerve" can refer exclusively to the connection to muscles, excluding other organs. The vast majority of nerves contain both sensory and motor fibers and are therefore called mixed nerves.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.
It binds REV-ERB alpha and REV-ERB beta and changes the expression of genes tied to metabolism and circadian rhythm. These changes can affect mitochondria and energy use in animal models. The exact chain from receptor binding to physiological outcome is still being mapped.
No reliable human trials show that SR9009 improves athletic performance. Some rodent studies report endurance changes, but these results are not proof of human benefit. Its use in sport is prohibited, and quality and safety data are lacking.
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.